Were Analysts Bullish DexCom, Inc. (NASDAQ:DXCM) This Week?

DexCom, Inc. (NASDAQ:DXCM) Logo
Investors sentiment decreased to 1 in 2019 Q2. Its down 0.07, from 1.07 in 2019Q1. It worsened, as 51 investors sold DexCom, Inc. shares while 115 reduced holdings. 50 funds opened positions while 116 raised stakes. 84.91 million shares or 12.27% less from 96.78 million shares in 2019Q1 were reported.
Nomura Incorporated holds 0.01% in DexCom, Inc. (NASDAQ:DXCM) or 8,414 shares. Morgan Stanley reported 3.06 million shares. Grandeur Peak Advsrs Limited Liability Co has 3,450 shares. 1,483 are owned by Profund Advsr Lc. Brown Advisory accumulated 2.68M shares. Blair William Il holds 1.14M shares or 0.97% of its portfolio. Broadfin Cap Limited Liability Company accumulated 63,300 shares. Renaissance Tech Ltd Com owns 300,943 shares or 0.04% of their US portfolio. Pitcairn Co accumulated 22,461 shares or 0.34% of the stock. Amalgamated Bancorp stated it has 20,030 shares or 0.07% of all its holdings. Private Wealth Advsrs has 0.08% invested in DexCom, Inc. (NASDAQ:DXCM). Hodges Management Inc, Texas-based fund reported 4,895 shares. Numerixs Invest stated it has 0.25% in DexCom, Inc. (NASDAQ:DXCM). Deutsche Bankshares Ag holds 428,409 shares. Essex Investment Mgmt Limited Com reported 3,283 shares or 0.07% of all its holdings.

DexCom, Inc. (NASDAQ:DXCM) Ratings Coverage

Among 6 analysts covering DexCom (NASDAQ:DXCM), 5 have Buy rating, 0 Sell and 1 Hold. Therefore 83% are positive. DexCom has $19500 highest and $15000 lowest target. $177.43’s average target is 14.21% above currents $155.35 stock price. DexCom had 9 analyst reports since April 30, 2019 according to SRatingsIntel. Robert W. Baird maintained it with “Outperform” rating and $18600 target in Thursday, August 1 report. The stock of DexCom, Inc. (NASDAQ:DXCM) has “Outperform” rating given on Tuesday, September 3 by BMO Capital Markets. Bank of America maintained DexCom, Inc. (NASDAQ:DXCM) on Thursday, August 1 with “Buy” rating. UBS maintained the shares of DXCM in report on Thursday, August 1 with “Neutral” rating. The company was maintained on Thursday, August 1 by Raymond James. The firm has “Overweight” rating given on Thursday, August 1 by JP Morgan. The stock of DexCom, Inc. (NASDAQ:DXCM) earned “Outperform” rating by Robert W. Baird on Thursday, August 29. Below is a list of DexCom, Inc. (NASDAQ:DXCM) latest ratings and price target changes.

20/09/2019 Broker: BidaskScore Rating: Buy Upgrade
03/09/2019 Broker: BMO Capital Markets Rating: Outperform Old Target: $180.0000 New Target: $190.0000 Maintain
29/08/2019 Broker: Robert W. Baird Rating: Outperform Old Target: $186.0000 New Target: $195.0000 Maintain
01/08/2019 Broker: Bank of America Rating: Buy Old Target: $162.0000 New Target: $185.0000 Maintain
01/08/2019 Broker: Robert W. Baird Rating: Outperform Old Target: $180.0000 New Target: $186.0000 Maintain
01/08/2019 Broker: JP Morgan Rating: Overweight Old Target: $170.0000 New Target: $190.0000 Maintain
01/08/2019 Broker: UBS Rating: Neutral Old Target: $140.0000 New Target: $160.0000 Maintain
01/08/2019 Broker: Raymond James Rating: Outperform Old Target: $150.0000 New Target: $172.0000 Maintain
30/04/2019 Broker: Inc. – Common Stock Rating: Ubs New Target: $150.0000 140.0000

The stock increased 0.58% or $0.89 during the last trading session, reaching $155.35. About 385,335 shares traded. DexCom, Inc. (NASDAQ:DXCM) has risen 67.97% since October 12, 2018 and is uptrending. It has outperformed by 67.97% the S&P500.

DexCom, Inc., a medical device company, together with its subsidiaries, focuses on the design, development, and commercialization of continuous glucose monitoring systems in the United States and internationally. The company has market cap of $14.17 billion. The firm offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers in the hospital for the treatment of patients with and without diabetes. It currently has negative earnings. The Company’s products include DexCom G4 PLATINUM system for continuous use by adults with diabetes; DexCom G4 PLATINUM with Share, a remote monitoring system; and DexCom G5 Mobile, a CGM system that directly communicates to a patientÂ’s mobile and its data can be integrated with DexCom CLARITY, which is a next generation cloud reporting software for personalized, easy-to-understand analysis of trends to improve diabetes management.

More notable recent DexCom, Inc. (NASDAQ:DXCM) news were published by: Seekingalpha.com which released: “DexCom Is Priced For Perfection – Seeking Alpha” on November 21, 2018, also Seekingalpha.com with their article: “DexCom: High Growth, Intense Competition, Extreme Valuation – Seeking Alpha” published on June 28, 2019, Seekingalpha.com published: “DexCom Q2 top line up 39%, guidance raised – Seeking Alpha” on July 31, 2019. More interesting news about DexCom, Inc. (NASDAQ:DXCM) were released by: Businesswire.com and their article: “Dexcom Schedules Third Quarter 2019 Earnings Release and Conference Call for November 6, 2019 at 4:30 p.m. Eastern Time – Business Wire” published on October 09, 2019 as well as Seekingalpha.com‘s news article titled: “Dexcom prevails in patent dispute with WaveForm Tech – Seeking Alpha” with publication date: August 23, 2019.

DexCom, Inc. (NASDAQ:DXCM) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.